{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:59:03Z","timestamp":1785484743708,"version":"3.56.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcyt.2026.102912","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:34:19Z","timestamp":1778945659000},"page":"102912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High affinity CD16v\/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases"],"prefix":"10.1016","volume":"28","author":[{"given":"Lisa","family":"Guerrettaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-3247","authenticated-orcid":false,"given":"Kun-Y.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Palomino La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ianne C.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Stromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Conerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Raymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102912_bib0001","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.948125","article-title":"A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ malignancies","volume":"31","author":"Parums","year":"2025","journal-title":"Med Sci Monit"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102912_bib0002","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0004","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102912_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1368","article-title":"Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis","volume":"12","author":"Wang","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"10306","key":"10.1016\/j.jcyt.2026.102912_bib0006","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102912_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0009","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102912_bib0010","article-title":"Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease","volume":"76","author":"Hagen","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102912_bib0011","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102912_bib0012","doi-asserted-by":"crossref","first-page":"992232","DOI":"10.3389\/fimmu.2022.992232","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"705","key":"10.1016\/j.jcyt.2026.102912_bib0013","doi-asserted-by":"crossref","first-page":"eade3341","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0014","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102912_bib0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102912_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Coenon","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.jcyt.2026.102912_bib0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","article-title":"Activation, coactivation, and costimulation of resting human natural killer cells","volume":"214","author":"Bryceson","year":"2006","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102912_bib0018","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1038\/bcj.2016.67","article-title":"Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma","volume":"6","author":"He","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5045\/br.2014.49.3.162","article-title":"Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"49","author":"Kim","year":"2014","journal-title":"Blood Res"},{"issue":"15","key":"10.1016\/j.jcyt.2026.102912_bib0020","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1158\/1078-0432.CCR-18-3270","article-title":"Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large b-cell lymphoma patients treated with immunochemotherapy","volume":"25","author":"Klanova","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102912_bib0021","doi-asserted-by":"crossref","first-page":"645478","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102912_bib0022","doi-asserted-by":"crossref","first-page":"624687","DOI":"10.3389\/fimmu.2021.624687","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13075-022-02731-y","article-title":"Increased oxidative stress contributes to impaired peripheral CD56(dim)CD57(+) NK cells from patients with systemic lupus erythematosus","volume":"24","author":"Lu","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jcyt.2026.102912_bib0024","doi-asserted-by":"crossref","first-page":"104343","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1250","article-title":"Natural killer cells in inflammatory autoimmune diseases","volume":"10","author":"Yang","year":"2021","journal-title":"Clin Transl Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102912_bib0026","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jcyt.2026.102912_bib0027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102912_bib0028","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102912_bib0029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr2.11466","article-title":"Predicting sustained clinical response to rituximab in moderate to severe systemic manifestations of primary sjogren syndrome","volume":"4","author":"Pepple","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102912_bib0030","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102912_bib0032","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102912_bib0033","first-page":"774","article-title":"AlloNK\u00ae cell therapy \u00b1 Rituximab in patients with relapsed or refractory Non-Hodgkin lymphoma. ASGCT 28th Annual Meeting Abstracts","volume":"33","author":"Farooq","year":"2025","journal-title":"Mol Ther"},{"issue":"16","key":"10.1016\/j.jcyt.2026.102912_bib0034","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2025.43.16_suppl.7008","article-title":"Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)","volume":"43","author":"Maakaron","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102912_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2026.102912_bib0036","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.humimm.2022.10.010","article-title":"Cord blood stem cell-generated KIR(+)NK cells effectively target leukemia cell lines","volume":"84","author":"Dizaji Asl","year":"2023","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2014.10.014","article-title":"Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture","volume":"21","author":"Tomchuck","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0041","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102912_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0043","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/j.jtct.2025.12.535","article-title":"A multi-center, phase 1\/2 trial of AlloNK cell therapy \u00b1 Rituximab in patients with relapsed or refractory non\u2011Hodgkin lymphoma","volume":"32","author":"Farooq","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0044","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s40425-019-0751-5","article-title":"Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells","volume":"7","author":"Bonanni","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.jcyt.2026.102912_bib0045","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102912_bib0046","first-page":"1513","article-title":"AlloNK: a scalable and consistent NK cell therapy in development for treatment of oncology and autoimmune diseases. ASGCT 28th Annual Meeting Abstracts","volume":"33","author":"Moreno","year":"2025","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0047","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri1266","article-title":"Human antibody-Fc receptor interactions illuminated by crystal structures","volume":"4","author":"Woof","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1753425908101404","article-title":"Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells","volume":"15","author":"Levy","year":"2009","journal-title":"Innate Immun"},{"issue":"13","key":"10.1016\/j.jcyt.2026.102912_bib0049","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood-2002-04-1058","article-title":"SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells","volume":"100","author":"Galandrini","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102912_bib0050","first-page":"52502","article-title":"Super-resolution imaging of the natural killer cell immunological synapse on a glass-supported planar lipid bilayer","volume":"96","author":"Zheng","year":"2015","journal-title":"J Vis Exp"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102912_bib0051","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/eji.200737266","article-title":"Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells","volume":"37","author":"Cecchetti","year":"2007","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0052","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.12617","article-title":"Lipid rafts in immune signalling: current progress and future perspective","volume":"149","author":"Varshney","year":"2016","journal-title":"Immunology"},{"issue":"18","key":"10.1016\/j.jcyt.2026.102912_bib0053","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102912_bib0054","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcyt.2023.11.009","article-title":"Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity","volume":"26","author":"van Hauten","year":"2024","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0056","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0057","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2249.2005.02822.x","article-title":"Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients","volume":"141","author":"Green","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0058","first-page":"59","article-title":"Comparison of natural killing with antibody dependent cell mediated cytotoxicity in patients with systemic lupus erythematosus","volume":"9","author":"Kozlowski","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jcyt.2026.102912_bib0059","doi-asserted-by":"crossref","first-page":"622306","DOI":"10.3389\/fimmu.2021.622306","article-title":"The Role of Natural Killer Cells in Autoimmune Diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0060","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3899\/jrheum.150644","article-title":"Altered natural killer cell subsets in seropositive arthralgia and early rheumatoid arthritis are associated with autoantibody status","volume":"43","author":"Chalan","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0061","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1038\/s41598-020-62654-z","article-title":"Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15","volume":"10","author":"Lin","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102912_bib0062","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102912_bib0063","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102912_bib0064","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102912_bib0065","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102912_bib0066","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102912_bib0067","first-page":"410","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis Reply","volume":"393","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102912_bib0068","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.intimp.2018.07.026","article-title":"CXCR3-deficient natural killer cells fail to migrate to B16F10 melanoma cells","volume":"63","author":"Kim","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0069","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3899\/jrheum.090769","article-title":"CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis","volume":"37","author":"Kuan","year":"2010","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102912_bib0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41423-021-00759-9","article-title":"Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity","volume":"19","author":"Min","year":"2022","journal-title":"Cell Mol Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600873X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600873X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:18:45Z","timestamp":1785482325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600873X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S146532492600873X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102912","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High affinity CD16v\/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell and Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102912"}}